Previous Page  43 / 52 Next Page
Information
Show Menu
Previous Page 43 / 52 Next Page
Page Background

43

Oftalmopatía De Graves En Edad Pediátrica. Revisión De La Literatura Y Reporte De 5 Casos

BIBLIOGRAFÍA

1.

Eha, J., Pitz, S., & Pohlenz, J. (2010). Clinical

features of pediatric Graves’ orbitopathy.

International Ophthalmology, 30(6), 717–721.

2.

Krassas, G. E., Segni, M., & Wiersinga, W. M.

(2005). Childhood Graves’ ophthalmopathy:

results of a European questionnaire study.

European Journal of Endocrinology, 153(4),

515–521.

3.

Bartalena, L., Pinchera, A., & Marcocci, C. (2000).

Management of Graves’ ophthalmopathy: reality

and perspectives. Endocrine Reviews, 21(2),

168–199.

4.

Smith, T. J., & Hegedüs, L. (2016). Graves’

Disease. New England Journal of Medicine,

375(16), 1552–1565.

5.

Sahlı, E., & Gündüz, K. (2017). Thyroid-associated

Ophthalmopathy. Türk Oftalmoloji Dergisi, 47(2),

94–105.

6.

Mendoza, C., & Lacourt, P. (2015). Orbitopatía

de Graves en pediatría. Revista Médica de Chile,

143(8), 1034–1041.

7.

Bartalena, L., Marcocci, C., & Pinchera, A. (2002).

Graves’ ophthalmopathy: a preventable disease?

European Journal of Endocrinology, 146(4),

457–461.

8.

Marcocci, C., & Marinò, M. (2012). Treatment

of mild, moderate-to-severe and very severe

Graves’ orbitopathy. Best Practice & Research

Clinical Endocrinology & Metabolism, 26(3),

325–337.

9.

Baldeschi, L., Dickinson, A., Eckstein, A.,

Kendall-Taylor, P., Marcocci, C., … Wiersinga, W.

M. (2008). Consensus statement of the European

Group on Graves’ orbitopathy (EUGOGO) on

management of GO. European Journal of

Endocrinology, 158(3), 273–285.

10.

Ferreira, C., Meireles, C., Marques, O., &

Antunes, A. (2017). Therapeutic challenge

of a paediatric case of Graves’ disease with

severe ophthalmopathy. BMJ Case Reports,

bcr2017219269.

11.

Papp, A., Vasserot-Merle, C., Dorner, G., &

Paridaens, D. (2016). Severe pediatric Graves

orbitopathy in adolescents of African origin.

Orbit, 35(6), 317–320.

12.

Sadeghi, Y., Obéric, A., Theintz, G., & Hamédani,

M. (2017). Gravesʼ Ophthalmopathy in a

Paediatric Population. Klinische Monatsblätter

für Augenheilkunde, 234(04), 591–594.

13.

Lai, A., Sassi, L., Compri, E., Marino, F., Sivelli,

P., Piantanida, E., … Bartalena, L. (2010).

Lower Dose Prednisone Prevents Radioiodine-

Associated Exacerbation of Initially Mild or

Absent Graves’ Orbitopathy: A Retrospective

Cohort Study. The Journal of Clinical

Endocrinology & Metabolism, 95(3), 1333–1337

14.

Novaes, P., Diniz Grisolia, A. B., & Smith,

T. J. (2016). Update on thyroid-associated

Ophthalmopathy with a special emphasis

on the ocular surface. Clinical Diabetes and

Endocrinology, 2(1).

15.

Bartley, G. B. (2011). Rundle and His Curve.

Archives of Ophthalmology, 129(3), 356.

16.

Bartley, G. B., Fatourechi, V., Kadrmas, E. F.,

Jacobsen, S. J., Ilstrup, D. M., Garrity, J. A.,

& Gorman, C. A. (1996). Clinical features of

Graves’ ophthalmopathy in an incidence cohort.

American Journal of Ophthalmology, 121(3),

284–290.

17.

Szczapa-Jagustyn, J., Gotz-Więckowska, A.,

& Kociecki, J. (2016). An update on thyroid-

associated ophthalmopathy in children and

adolescents. Journal of Pediatric Endocrinology

and Metabolism, 29(10).

18.

18. Jarusaitiene, D., Verkauskiene, R.,

Jasinskas, V., & Jankauskiene, J. (2016).

Predictive Factors of Development of Graves’

Ophthalmopathy for Patients with Juvenile

Graves’ Disease. International Journal of

Endocrinology, 2016, 1–9.

19.

Holt, H., Hunter, D. G., Smith, J., & Dagi, L.

R. (2008). Pediatric Graves’ ophthalmopathy:

The pre- and postpubertal experience.

Journal of American Association for Pediatric

Ophthalmology and Strabismus, 12(4), 357–360.

20.

Jang, S. Y., Shin, D. Y., Lee, E. J., Choi, Y. J., Lee,

S. Y., & Yoon, J. S. (2013). Correlation between

TSH Receptor Antibody Assays and Clinical

Manifestations of Graves’ Orbitopathy. Yonsei

Medical Journal, 54(4), 1033.

21.

Bartalena, L., Burch, H. B., Burman, K. D., &

Kahaly, G. J. (2016). A 2013 European survey of

clinical practice patterns in the management of

Graves’ disease. Clinical Endocrinology, 84(1),

115–120.

22.

Mourits, M. P., Prummel, M. F., Wiersinga, W.

M., & Koornneef, L. (1997). Clinical activity score

as a guide in the management of patients with

Graves’ ophthalmopathy. Clinical Endocrinology,

47(1), 9–14.

23.

Dolman, P. J., & Rootman, J. (2006). VISA

Classification for Graves Orbitopathy: Ophthalmic

Plastic & Reconstructive Surgery, 22(5), 319–324.

24.

Bartalena, L., Baldeschi, L., Boboridis, K.,

Eckstein, A., Kahaly, G. J., Marcocci, C., …

(2016). The 2016 European Thyroid Association/

European Group on Graves’ Orbitopathy

Guidelines for the Management of Graves’

Orbitopathy. European Thyroid Journal, 5(1),

9–26.

25.

Bartalena, L. (2005). Glucocorticoids for Graves’

Ophthalmopathy: How and When. The Journal

of Clinical Endocrinology & Metabolism, 90(9),

5497–5499.

26.

Ebner, R. (2004). Treatment of thyroid associated

ophthalmopathy with periocular injections of

triamcinolone. British Journal of Ophthalmology,

88(11), 1380–1386.